3 Engineering Consultancy Company, Hotels Company and Pharmaceutical Maker Stocks With a Strong Future Roadmap: Engineers India, Lemon Tree Hotels and Lupin

Engineering consultancy, hotel and pharma stocks offer a focused view of a sector where demand keeps widening. Engineers India, Lemon Tree Hotels and Lupin cover an engineering consultancy company, a hotels company and a pharmaceutical maker.

This list covers three engineering consultancy, hotel and pharma stocks with complete current figures: Engineers India, Lemon Tree Hotels and Lupin. Every figure comes from the latest reported financials and the 11 November 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Engineering Consultancy, Hotel and Pharma Stocks?

Engineering consultancy, hotel and pharma stocks are listed companies that design and manage refinery, petrochemical and infrastructure projects, run mid priced hotels across many cities, and make branded and generic medicines for India and global markets. Their earnings depend on project awards, hotel occupancy and prescription demand.

Engineering Consultancy, Hotel and Pharma Stocks at a Glance

On valuation, all three trade at a P/E below their industry P/E, which means the market is pricing them at a lower multiple than their peer group. Readers comparing engineering consultancy, hotel and pharma stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.

Why Do Engineering Consultancy, Hotel and Pharma Stocks Have a Strong Roadmap in India?

Engineering consultancy, hotel and pharma stocks have a strong roadmap in India because continued investment in refining and infrastructure, growing domestic travel and rising demand for quality medicines keep widening the market for these companies.

• Engineering consultancy. Large plants need expert design and oversight.
• Hotels. Business and leisure travel keep rooms busy.
• Pharma. Generic and branded medicines reach more markets.

Why Engineers India Features Among These Engineering Consultancy, Hotel and Pharma Stocks

Among the engineering consultancy, hotel and pharma stocks on this list, Engineers India is a public sector engineering consultancy and project company that provides design, project management and construction services to oil, gas, petrochemical, fertiliser and infrastructure clients.

Revenue rose from Rs 3,043 crore in FY22 to Rs 4,123 crore in FY26, a compound annual growth rate of 7.9%. Net profit grew from Rs 343 crore in FY22 to Rs 692 crore in FY26, which works out to a compound annual growth rate of 19.2%.

The company has a return on equity of 22.0%, a debt to equity ratio of 0.01 and a market capitalisation of Rs 15,096 crore. The stock trades at a P/E of 19.2, below the industry P/E of 22.7.

Roadmap: The company is involved in refinery expansions and new petrochemical projects and is widening its work in green energy, hydrogen and infrastructure. A debt-free balance sheet and a strong order book give it capacity to take on large mandates.

What to watch: Monitor order inflow from refinery and petrochemical projects and execution of existing mandates.

Why Lemon Tree Hotels Features Among These Engineering Consultancy, Hotel and Pharma Stocks

Among the plant design, mid price stay and medicine shares on this list, Lemon Tree Hotels is one of India's largest mid-priced hotel chains, operating and managing hotels under the Lemon Tree, Red Fox, Aurika and Keys brands.

In the June 2026 quarter, revenue grew 9.2% year on year to Rs 347 crore, while net profit rose 19.2% to Rs 57.3 crore. Revenue rose from Rs 408 crore in FY22 to Rs 1,465 crore in FY26, a compound annual growth rate of 37.7%.

Net profit grew from Rs 141 crore in FY23 to Rs 288 crore in FY26, which works out to a compound annual growth rate of 27.1%. The company has a return on equity of 16.3%, a debt to equity ratio of 1.44 and a market capitalisation of Rs 8,849 crore. The stock trades at a P/E of 29.7, below the industry P/E of 37.9.

Roadmap: The company is adding rooms mainly through management contracts, which grow its footprint with limited capital outlay. Rising domestic travel and a focus on the mid-priced segment support healthy occupancy.

What to watch: Monitor new room signings and openings and average room rate trends.

Why Lupin Features Among These Engineering Consultancy, Hotel and Pharma Stocks

Among the three companies on this list, Lupin is a Mumbai-headquartered global pharmaceutical company with a presence in branded generics in India, complex generics and specialty products in the United States, and active ingredients, with strength in respiratory, cardiovascular, anti-diabetic and anti-infective therapies.

The company has a return on equity of 23.8%, a debt to equity ratio of 0.29 and a market capitalisation of Rs 89,343 crore. The stock trades at a P/E of 16.1, below the industry P/E of 36.0.

Revenue rose from Rs 16,616 crore in FY22 to Rs 29,039 crore in FY26, a compound annual growth rate of 15.0%. Net profit grew from Rs 1,936 crore in FY24 to Rs 5,355 crore in FY26, which works out to a compound annual growth rate of 66.3%. In the June 2026 quarter, revenue grew 32.5% year on year to Rs 8,407 crore, while net profit rose 16.0% to Rs 1,417 crore.

Roadmap: The company is building its pipeline of complex generics, inhalation products and biosimilars, and is widening its specialty portfolio in the United States. Its large Indian branded business and a presence in over 100 markets spread revenue across regions and therapies.

What to watch: Track key launches in the United States, especially in inhalation and complex injectables, and the growth of the India branded business.

Engineers India vs Lemon Tree Hotels vs Lupin on Key Financials

The table below sets the three engineering consultancy, hotel and pharma stocks side by side on revenue, profit and margin, using reported figures.

Lupin posts the highest return on equity in this group at 23.8%. Lupin has the largest FY26 revenue at Rs 29,039 crore, and Lemon Tree Hotels shows the fastest revenue growth with a 37.7% compound annual rate. A useful habit with engineering consultancy, hotel and pharma stocks is to check each new quarterly result against the capacity plans the company described earlier.

Key Risks to Check Before Investing in Engineering Consultancy, Hotel and Pharma Stocks

Every theme carries risks that deserve a check before any decision. For these engineering consultancy, hotel and pharma stocks, the main points are: Long-term plant design, mid price stay and medicine shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Order timing. Project awards can shift between periods.
• Travel cycles. Bookings and occupancy follow travel demand.
• Pricing pressure. Generic prices can change by market.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter engineering consultancy, hotel and pharma stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Engineering Consultancy, Hotel and Pharma Stocks

Engineering consultancy, hotel and pharma stocks reward patient research into demand, execution and financial strength. Engineers India, Lemon Tree Hotels and Lupin each have a clear plan to grow. Based on the 11 November 2026 close, Engineers India trades at Rs 311.2, Lemon Tree Hotels at Rs 115.1 and Lupin at Rs 2,023.4. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these engineering consultancy, hotel and pharma stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track engineering consultancy, hotel and pharma stocks, set price alerts and get research-backed stock ideas.

What are engineering consultancy, hotel and pharma stocks?

Ans. Engineering consultancy, hotel and pharma stocks are listed companies that design and manage refinery, petrochemical and infrastructure projects, run mid priced hotels across many cities, and make branded and generic medicines for India and global markets. Their earnings depend on project awards, hotel occupancy and prescription demand. This list looks at three of them, Engineers India, Lemon Tree Hotels and Lupin, using reported FY22 to FY26 financials and the 11 November 2026 closing prices.

Which engineering consultancy, hotel and pharma stocks are covered in this list?

Ans. This list covers Engineers India, Lemon Tree Hotels and Lupin. Based on the 11 November 2026 close, Engineers India traded at Rs 311.2, Lemon Tree Hotels at Rs 115.1 and Lupin at Rs 2,023.4. Their return on equity ranges from 16.3% to 23.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.9% to 37.7%.

Why do engineering consultancy, hotel and pharma stocks have a strong future roadmap in India?

Ans. Engineering consultancy, hotel and pharma stocks have a strong roadmap in India because continued investment in refining and infrastructure, growing domestic travel and rising demand for quality medicines keep widening the market for these companies. The main drivers are as follows. Engineering consultancy. Large plants need expert design and oversight. Hotels. Business and leisure travel keep rooms busy. Pharma. Generic and branded medicines reach more markets. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Engineers India performed financially?

Ans. Revenue rose from Rs 3,043 crore in FY22 to Rs 4,123 crore in FY26, a compound annual growth rate of 7.9%. Net profit grew from Rs 343 crore in FY22 to Rs 692 crore in FY26, which works out to a compound annual growth rate of 19.2%. The company has a return on equity of 22.0%, a debt to equity ratio of 0.01 and a market capitalisation of Rs 15,096 crore. The stock trades at a P/E of 19.2, below the industry P/E of 22.7. Looking ahead, the company is involved in refinery expansions and new petrochemical projects and is widening its work in green energy, hydrogen and infrastructure. A debt-free balance sheet and a strong order book give it capacity to take on large mandates.

How has Lemon Tree Hotels performed financially?

Ans. Revenue rose from Rs 408 crore in FY22 to Rs 1,465 crore in FY26, a compound annual growth rate of 37.7%. Net profit grew from Rs 141 crore in FY23 to Rs 288 crore in FY26, which works out to a compound annual growth rate of 27.1%. In the June 2026 quarter, revenue grew 9.2% year on year to Rs 347 crore, while net profit rose 19.2% to Rs 57.3 crore. The company has a return on equity of 16.3%, a debt to equity ratio of 1.44 and a market capitalisation of Rs 8,849 crore. The stock trades at a P/E of 29.7, below the industry P/E of 37.9. Looking ahead, the company is adding rooms mainly through management contracts, which grow its footprint with limited capital outlay. Rising domestic travel and a focus on the mid-priced segment support healthy occupancy.

How has Lupin performed financially?

Ans. Revenue rose from Rs 16,616 crore in FY22 to Rs 29,039 crore in FY26, a compound annual growth rate of 15.0%. Net profit grew from Rs 1,936 crore in FY24 to Rs 5,355 crore in FY26, which works out to a compound annual growth rate of 66.3%. In the June 2026 quarter, revenue grew 32.5% year on year to Rs 8,407 crore, while net profit rose 16.0% to Rs 1,417 crore. The company has a return on equity of 23.8%, a debt to equity ratio of 0.29 and a market capitalisation of Rs 89,343 crore. The stock trades at a P/E of 16.1, below the industry P/E of 36.0. Looking ahead, the company is building its pipeline of complex generics, inhalation products and biosimilars, and is widening its specialty portfolio in the United States. Its large Indian branded business and a presence in over 100 markets spread revenue across regions and therapies.

What risks should investors check before buying engineering consultancy, hotel and pharma stocks?

Ans. Investors should check a few risks before buying engineering consultancy, hotel and pharma stocks. Order timing. Project awards can shift between periods. Travel cycles. Bookings and occupancy follow travel demand. Pricing pressure. Generic prices can change by market. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of engineering consultancy, hotel and pharma stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 11 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.